Categories: Health

Bharat Biotech’s Covaxin proves 93.4% effective against Covid-19, works against Delta variant too

<p>
Phase-III trials of the India-made Covaxin vaccine show that it is 93.4% effective against severe symptomatic COVID-19 and works against the Delta variant as well, Hyderabad- based pharma firm Bharat Biotech announced on Saturday.</p>
<p>
The data demonstrated 65.2% protection against the Delta variant, first identified in India, that led to a surge in infections during the second wave in April and May. The variant is also on the rise in countries such as the US and Europe.</p>
<p>
India's home-grown vaccine manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and Indian Institute of Virology, also showed an effectiveness of 77.8% against symptomatic COVID-19 in the trial.</p>
<p>
<strong>Also read: </strong> <a href="https://www.indianarrative.com/health-news/who-approval-for-bharat-biotech-s-covaxin-likely-in-mid-august-99354.html">WHO approval for Bharat Biotech’s Covaxin likely in mid-August</a></p>
<p>
The Phase-III data came as Ocugen Inc , which is co-developing Covaxin with Bharat Biotech for the U.S. market, prepares to file a request for full U.S. approval.</p>
<p>
Bharat Biotech also said the safety analysis for Covaxin demonstrates adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events.</p>
<p>
Bharat Biotech which has been making 10 million doses of Covaxin a month will now step up production to 23 million doses a month. Besides, the government has asked five public sector companies to start producing the vaccine as well so that it can be made more widely available under the accelerated vaccination drive.</p>
<p>
<strong>Also read:</strong>  <a href="https://www.indianarrative.com/health-news/zydus-seeks-govt-nod-for-use-of-new-india-made-vaccine-as-trials-have-been-completed-99201.html">Zydus seeks govt nod for use of new India-made vaccine as trials have been completed</a></p>
<p>
Last month, vaccine maker AstraZeneca Plc also said its vaccine was effective against the Delta and Kappa variants, citing a study.</p>
<p>
India has been administering the AstraZeneca vaccine, made domestically by the Serum Institute of India under the Covishield brand. While 70 million doses a month of the vaccine are being currently manufactured, the output will be increased to around nearly 100 million doses in July .</p>
<p>
 </p>
<p>
 </p>

IN Bureau

Recent Posts

India charts bold path to global 6G leadership, Minister Scindia reviews progress in Bengaluru

Union Minister for Communications Jyotiraditya Scindia chaired a key meeting with the Bharat 6G Alliance…

12 hours ago

Japanese envoy urges Taliban to reopen schools for girls, warns of healthcare crisis

Japanese Ambassador in Kabul, Takayoshi Kuromaya, has called on the Taliban government in Afghanistan to…

13 hours ago

Digital India Foundation opposes Pakistan’s membership bid to AI Alliance Network; cites security concerns

The Digital India Foundation (DIF), a founding member of the AI Alliance Network (AIANET), has…

13 hours ago

Gold’s rally awaits clarity on US interest rates and dollar weakness: Report

Current bullion market is focusing on a combination of factors which includes direction of US…

16 hours ago

“You show me one photograph…” NSA Ajit Doval slams foreign media’s coverage of Operation Sindoor

National Security Advisor Ajit Doval on Friday slammed foreign media for their reportage of Operation…

16 hours ago

Russia: Bharat Utsav celebrates India’s rich heritage, culture and traditions

The Bharat Utsav, a festival celebrating India's rich culture, heritage, and tradition, has begun in…

18 hours ago